{"product_id":"retatrutide-20-mg","title":"Retatrutide","description":"\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:0 0 .4em;font-family:inherit;\"\u003eSummary\u003c\/p\u003e\n\u003cp style=\"font-size:1.05em;line-height:1.65;margin:0 0 1.2em;\"\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e is one of the most potent research peptides in the \u003cstrong\u003emetabolic and weight control\u003c\/strong\u003e field: it is studied for its role in \u003cstrong\u003efat burning, energy expenditure, and body recomposition\u003c\/strong\u003e. Technically, it is a \u003cstrong\u003etriple agonist\u003c\/strong\u003e peptide (LY-3437943) that simultaneously activates three key metabolic receptors—GLP-1R, GIPR, and GCGR—a unique combination among incretin agonists that has positioned it as one of the most promising candidates in current research.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat is it being researched for?\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Reduction of body weight and body composition\u003c\/li\u003e\n\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Energy expenditure and fat oxidation\u003c\/li\u003e\n\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Appetite and satiety regulation\u003c\/li\u003e\n\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Blood glucose control and insulin sensitivity\u003c\/li\u003e\n\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Hepatic lipid profile\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eCycle and break\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:12px;margin:0 0 1.4em;flex-wrap:wrap;\"\u003e\n\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eCycle\u003c\/div\u003e\n\n    \u003cdiv style=\"font-weight:600;\"\u003eContinuous until Goal\u003c\/div\u003e\n\n  \u003c\/div\u003e\n\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eBreak\u003c\/div\u003e\n\n    \u003cdiv style=\"font-weight:600;\"\u003eNot required\u003c\/div\u003e\n\n  \u003c\/div\u003e\n\n\n\u003c\/div\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eMechanism of action\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eTriple incretin agonism (GLP-1R \/ GIPR \/ GCGR)\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eUnlike single or dual agonists, Retatrutide simultaneously activates three pathways: GLP-1 receptor (satiety and insulin), GIP receptor (insulin sensitivity), and glucagon receptor (GCGR, which adds energy expenditure and fat mobilization).\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eWeight reduction and metabolic control\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eThe sum of the three mechanisms translates into a greater effect on body weight and blood glucose than previous agonists in research models.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eEnergy expenditure and fat metabolism\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eThe glucagon component (GCGR) increases energy expenditure and promotes lipid oxidation, complementing the reduction in food intake mediated by GLP-1 and GIP.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eScientific evidence\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003eTriple agonism:\u003c\/strong\u003e Receptor studies confirm its balanced agonism on the three targets, the basis of its metabolic potency.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003eBody weight:\u003c\/strong\u003e In a phase 2 clinical trial (Jastreboff et al., NEJM, 2023), Retatrutide produced weight reductions of up to ~24% at 48 weeks, among the largest observed for an incretin agonist.\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003eEnergy expenditure:\u003c\/strong\u003e Preclinical models describe increased energy expenditure and improved hepatic lipid profile.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eProduct use\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eDue to its triple mechanism and outstanding clinical results, Retatrutide is a top-tier reference material in metabolic and weight control research. At \u003cstrong\u003ePeptido BioGenetic\u003c\/strong\u003e, we supply it as a high-purity peptide for laboratory use, with a Certificate of Analysis (COA) available upon request.\u003c\/p\u003e\n\n\u003cp style=\"margin:1.6em 0 0;padding:12px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e⚠️ Product intended exclusively for \u003cstrong\u003eresearch and laboratory use\u003c\/strong\u003e. Not suitable for human or veterinary consumption.\u003c\/p\u003e","brand":"PeptidoBioGenetic","offers":[{"title":"15 mg","offer_id":54603479646537,"sku":"RT15","price":197.0,"currency_code":"EUR","in_stock":true},{"title":"20 mg","offer_id":54603479679305,"sku":"RT20","price":231.0,"currency_code":"EUR","in_stock":true},{"title":"30 mg","offer_id":54760619049289,"sku":"RT30","price":279.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1016\/7507\/3865\/files\/principal-sin-fondo-removebg-preview.png?v=1782817358","url":"https:\/\/www.peptidobiogenetic.com\/en\/products\/retatrutide-20-mg","provider":"PeptidoBioGenetic","version":"1.0","type":"link"}